CSIMarket Company Name, Ticker, Competitors, else..
 
Journey Medical Corp  (NASDAQ: DERM)
Other Ticker:  
 
 
Price: $3.6600 $-0.13 -3.430%
Day's High: $3.99 Week Perf: -3.17 %
Day's Low: $ 3.65 30 Day Perf: -25.46 %
Volume (M): 52 52 Wk High: $ 6.89
Volume (M$): $ 190 52 Wk Avg: $4.72
Open: $3.83 52 Wk Low: $2.85



 Market Capitalization (Millions $) 75
 Shares Outstanding (Millions) 21
 Employees 20
 Revenues (TTM) (Millions $) 58
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Journey Medical Corp
Journey Medical Corporation is a company focused on developing and marketing innovative dermatological products. They specialize in providing solutions for a wide range of skin conditions, including acne, psoriasis, eczema, and more. Journey Medical Corporation works closely with dermatologists, healthcare providers, and patients to create effective treatment options that improve the lives of those suffering from skin conditions. The company is committed to advancing dermatology through research, innovation, and education, with the ultimate goal of empowering patients and improving their skin health.


   Company Address: 9237 E Via de Ventura Blvd. Scottsdale 85258 AZ
   Company Phone Number: 434-6670   Stock Exchange / Ticker: NASDAQ DERM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -2.93%    
BMY        1.68% 
JNJ        1.77% 
LLY   -9%    
MRK   -3.03%    
PFE   -1.87%    
• View Complete Report
   



Product Service News

Transformative Milestones in Dermatology FDA Approves Journey Medical?s Emrosi for Rosacea Management,

Published Mon, Nov 4 2024 12:01 PM UTC

Revolutionizing Rosacea Treatment: Journey Medical Corporation s Emrosi Receives FDA ApprovalIn a significant advancement for dermatological therapeutics, Journey Medical Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of rosacea. This newly approved...
Journey Medical Corporation

Deficit Despite Revenue Surge in the Fiscal Year Ending March 31 2024

Journey Medical Corporation, a pharmaceutical company focused on dermatological treatments, is making significant strides in the industry. Recently, the company presented data from a Phase 1 clinical trial at the 2024 American Academy of Dermatology Annual Meeting, showcasing the impact of their flagship product, DFD-29, on the microbial flora of healthy adults. This accomplishment highlights the company's commitment to advancing dermatological care and its importance within the dermatology community.
Additionally, the company's President and CEO, Claude Maraoui, will be presenting a corporate overview at the Planet MicroCap Showcase in Las Vegas. This event provides a platform for Journey Medical to showcase its products and achievements to potential investors and industry stakeholders.
Journey Medical Corporation

Journey Medical Corporation Reports a Shortfall of $-0.11 per Share in Fiscal Period

Journey Medical Corporation is a cutting-edge pharmaceutical company that focuses on developing innovative treatments for various dermatological conditions. The company recently made headlines with the presentation of data from a Phase 1 clinical trial assessing the impact of their flagship product, DFD-29, on the microbial flora of healthy adults. This milestone was shared at the prestigious 2024 American Academy of Dermatology (AAD) Annual Meeting, showcasing the company's commitment to advancing dermatological research and treatment options.
The Phase 1 clinical trial aimed to evaluate the impact of DFD-29, a modified release capsule containing 40 mg of Minocycline Hydrochloride, on the microbial flora of healthy adults. The trial results were presented at the AAD Annual Meeting, highlighting the importance of these findings within the dermatology community. The company successfully achieved all three primary endpoints of the trial, with subjects completing a 16-week treatment period without experiencing any significant safety issues. This is a significant achievement for Journey Medical Corporation and demonstrates the potential efficacy of DFD-29 in treating dermatological conditions.
Clinical Study

Augmenting Dermatology: Journey Medical Corporation's DFD-29 Shows Promise in Impacting Healthy Adults' Microbial Flora

Published Mon, Mar 11 2024 12:31 PM UTC

Journey Medical Corporation recently announced the presentation of data from a Phase 1 clinical trial assessing the impact of their flagship product, DFD-29, on the microbial flora of healthy adults. This significant milestone was shared at the 2024 American Academy of Dermatology (AAD) Annual Meeting. The company successfully achieved all three primary s of the trial, with ...
Product Service News

DFD-29: The Future of Rosacea Treatment Glimmers Bright as Journey Medical Corporation Seeks FDA approval.

Published Fri, Jan 5 2024 1:30 PM UTC

Journey Medical Corporation has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DFD-29, potentially heralding a breakthrough triumph in the treatment of Rosacea. If approved, DFD-29 has the potential to dominate the market as the best-in-class and the only oral medication that addresses both inflammatory lesions and erythema...






Journey Medical's Segments
Qbrexza    51.84 % of total Revenue
Accutane    27.32 % of total Revenue
Amzeeq    10.54 % of total Revenue
Zilxi    3.81 % of total Revenue
Other legacy    6.49 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com